Pontifax Management 4 G.p. (2015) Ltd. - Net Worth and Insider Trading
Pontifax Management 4 G.p. (2015) Ltd. Net Worth
The estimated net worth of Pontifax Management 4 G.p. (2015) Ltd. is at least $281 Million dollars as of 2024-11-29. Pontifax Management 4 G.p. (2015) Ltd. is the 10% Owner of Keros Therapeutics Inc and owns about 4,794,507 shares of Keros Therapeutics Inc (KROS) stock worth over $281 Million. Pontifax Management 4 G.p. (2015) Ltd. is also the 10% Owner of Eloxx Pharmaceuticals Inc and owns about 600 shares of Eloxx Pharmaceuticals Inc (ELOX) stock worth over $0. Details can be seen in Pontifax Management 4 G.p. (2015) Ltd.'s Latest Holdings Summary section.
Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Pontifax Management 4 G.p. (2015) Ltd. has not made any transactions after 2020-11-17 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.
Transaction Summary of Pontifax Management 4 G.p. (2015) Ltd.
Pontifax Management 4 G.p. (2015) Ltd. Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, Pontifax Management 4 G.p. (2015) Ltd. owns 3 companies in total, including Eloxx Pharmaceuticals Inc (ELOX) , Keros Therapeutics Inc (KROS) , and 89bio Inc (ETNB) .
Insider Ownership Summary of Pontifax Management 4 G.p. (2015) Ltd.
| Ticker | Comapny | Transaction Date | Type of Owner |
|---|---|---|---|
| ELOX | Eloxx Pharmaceuticals Inc | 2021-05-13 | 10 percent owner |
| KROS | Keros Therapeutics Inc | 2020-11-17 | 10 percent owner |
| ETNB | 89bio Inc | 2019-11-08 | 10 percent owner |
Pontifax Management 4 G.p. (2015) Ltd. Latest Holdings Summary
Pontifax Management 4 G.p. (2015) Ltd. currently owns a total of 2 stocks. Among these stocks, Pontifax Management 4 G.p. (2015) Ltd. owns 4,794,507 shares of Keros Therapeutics Inc (KROS) as of November 17, 2020, with a value of $281 Million and a weighting of 100%. Pontifax Management 4 G.p. (2015) Ltd. also owns 600 shares of Eloxx Pharmaceuticals Inc (ELOX) as of June 24, 2019, with a value of $0 and a weighting of 0%.
Latest Holdings of Pontifax Management 4 G.p. (2015) Ltd.
| Ticker | Comapny | Latest Transaction Date | Shares Owned | Current Price ($) | Current Value ($) |
|---|---|---|---|---|---|
| KROS | Keros Therapeutics Inc | 2020-11-17 | 4,794,507 | 58.55 | 280,718,385 |
| ELOX | Eloxx Pharmaceuticals Inc | 2019-06-24 | 600 | 0.00 | 0 |
Holding Weightings of Pontifax Management 4 G.p. (2015) Ltd.
Pontifax Management 4 G.p. (2015) Ltd. Form 4 Trading Tracker
According to the SEC Form 4 filings, Pontifax Management 4 G.p. (2015) Ltd. has made a total of 2 transactions in Keros Therapeutics Inc (KROS) over the past 5 years, including 2 buys and 0 sells. The most-recent trade in Keros Therapeutics Inc is the acquisition of 60,000 shares on November 17, 2020, which cost Pontifax Management 4 G.p. (2015) Ltd. around $3 Million.
According to the SEC Form 4 filings, Pontifax Management 4 G.p. (2015) Ltd. has made a total of 0 transactions in Eloxx Pharmaceuticals Inc (ELOX) over the past 5 years. The most-recent trade in Eloxx Pharmaceuticals Inc is the acquisition of 5,000 shares on June 24, 2019, which cost Pontifax Management 4 G.p. (2015) Ltd. around $2 Million.
Insider Trading History of Pontifax Management 4 G.p. (2015) Ltd.
- 1
Pontifax Management 4 G.p. (2015) Ltd. Trading Performance
GuruFocus tracks the stock performance after each of Pontifax Management 4 G.p. (2015) Ltd.'s buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Pontifax Management 4 G.p. (2015) Ltd. is 2.34%. GuruFocus also compares Pontifax Management 4 G.p. (2015) Ltd.'s trading performance to market benchmark return within the same time period. The performance of stocks bought by Pontifax Management 4 G.p. (2015) Ltd. within 3 months outperforms 2 times out of 4 transactions in total compared to the return of S&P 500 within the same period.
You can select different timeframes to see how Pontifax Management 4 G.p. (2015) Ltd.'s insider trading performs compared to the benchmark.
Performance of Pontifax Management 4 G.p. (2015) Ltd.
Average Return
Outperforming Transactions
| 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | 3 Years | |
|---|---|---|---|---|---|---|
| Return(%) | 13.56 | | | | | |
| Relative Return to S&P 500(%) | 10.91 | | | | | |
Pontifax Management 4 G.p. (2015) Ltd. Ownership Network
Pontifax Management 4 G.p. (2015) Ltd. Owned Company Details
What does Eloxx Pharmaceuticals Inc do?
Who are the key executives at Eloxx Pharmaceuticals Inc?
Pontifax Management 4 G.p. (2015) Ltd. is the 10 percent owner of Eloxx Pharmaceuticals Inc. Other key executives at Eloxx Pharmaceuticals Inc include HEAD OF R&D Vijay Modur , director & PRESIDENT AND CEO Sumit Aggarwal , and Chief Financial Officer Daniel E. Geffken .
Eloxx Pharmaceuticals Inc (ELOX) Insider Trades Summary
In summary, during the past 3 months, insiders sold 0 shares of Eloxx Pharmaceuticals Inc (ELOX) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Eloxx Pharmaceuticals Inc (ELOX) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.
Eloxx Pharmaceuticals Inc (ELOX)'s detailed insider trading history can be found in Insider Trading Tracker table.
Eloxx Pharmaceuticals Inc Insider Transactions
Pontifax Management 4 G.p. (2015) Ltd. Mailing Address
Above is the net worth, insider trading, and ownership report for Pontifax Management 4 G.p. (2015) Ltd.. You might contact Pontifax Management 4 G.p. (2015) Ltd. via mailing address: 14 Shenkar Street, Beit Ofek, Herzliya Pituach L3 46140.
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
